English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, March 13, 2023
歐康維視獲納入滬港通及深港通名單
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
Tuesday, February 14, 2023
欧康维视发布2022年度业绩盈利预喜
歐康維視發佈2022年度業績盈利預喜
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results
Friday, February 3, 2023
欧康维视研发的治疗干眼症的I类新药OT-202 I期临床试验完成
歐康維視研發的治療乾眼症的I類新藥OT-202 I期臨床試驗完成
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202
Wednesday, February 1, 2023
欧康维视自研新药OT-101于中国完成完成受试者入组
歐康維視自研新藥OT-101於中國完成完成受試者入組

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575